Merz North America has received the green light from the Food and Drug Administration for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients.
LexisNexis Risk Solutions Health Care’s Bobbie Riley and Bryan Eidex take a look at how pharmacies are tackling the growth of specialty and tools that should be in place when working with the high-dollar class of drugs.
The decision follows approval of a 10-year, $40 million tax incentive plan that was designed to lure Teva to the Garden State. The plan required Teva to keep 1,000 New Jersey jobs to reap the credits.
Adamis Pharmaceuticals has entered into an exclusive distribution and commercialization agreement with Swiss drug company Novartis’ Sandoz division to commercialize Adamis’ Symjepi.
Albertsons pharmacies were given agency approval to pilot Idaho’s new prescribing authority, which took effect July 1, making it the first large retail chain pharmacy in the nation to offer these expanded services.
Key factors in the decision included comments noting that the number of reference product lots biosimilar developers would need to purchase under the draft guidance if it were finalized could impact cost and efficiency.
